Civica Rx

Civica Rx is the nonprofit solution for reliable supplies of quality generic medications. Established by U.S. member hospitals and philanthropic organizations, Civica is the only pharmaceutical company created for the express purpose of preventing and mitigating drug shortages, ensuring the affordable supply of essential medications used in America’s ERs, ICUs and during surgeries. As of mid-2024, Civica has provided more than 185 million units of medications to help treat over 80 million patients.

Civica is making significant progress in bringing its new state-of-the-art Virginia sterile injectable manufacturing facility online. This facility will produce a steady supply of more than three dozen drugs currently in or near shortage status. It will also produce affordable biosimilar insulins, ensuring all Americans have access to lower cost, quality insulins, regardless of their insurance status.

The growing team on site is completing the various qualification and regulatory steps needed to bring each of the facility’s existing filling lines – one for vials and another for pre-filled syringes – to full operation and is installing a third line that will supply pre-filled pen cartridges. Combined, these three production lines will produce more than 200 million units annually, which will tremendously impact the availability and cost of these medicines throughout the country.

Learn more about Civica and join us in doing what is in the best interests of patients.

Civica is on a mission to deliver quality generic medicines—including insulin—at low cost. A new isolator-integrated vial filling line and nest filling line allow them to produce many different forms of injectables to pivot based on greatest need.
Fierce Healthcare’s Dave Muoio sat down with Allan Coukell, policy head at the hospital-backed nonprofit drug supplier Civica Rx.
Drug shortages continue to plague the United States. In many ways, the problem is the result of deficiencies in the current pharma market. But a model for addressing this problem is showing that it isn’t intractable.
1 Civica Way
Petersburg, VA 23805
  • Featured Employer
  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
In this episode of the Healthscape podcast, Ned McCoy, President & CEO at Civica, sits down with Ankit Aggarwal to discuss generic injectable drug shortages in the US and what Civica is doing to tackle the issue.

At Civica, we’re advancing a culture of innovation that is welcoming and inclusive for all, one that runs with solid, “ah-hah” ideas and celebrates exciting milestones and successes. Our purpose and mission are clear, and our values guide our actions. Learn more about what makes us tick.

Our team members make valuable contributions every day on behalf of patients. It is our privilege to invest in the health and well-being of our team members and help them take care of their families through our comprehensive benefits program.

Read what members of our team have to say about joining our company and building our new state-of-the-art manufacturing facility.

Watch how effective partnerships lead to solutions for patients.

NEWS
BioSpace has named 50 biopharma companies to its 2025 Best Places to Work list, including Moderna and Sutro Biopharma, whose executives share what makes their organizations special.
Looking for a quality control job? Check out these nine companies hiring life sciences professionals like you.
A new study provides the first empirical evidence that the not-for-profit manufacturer’s business model can lead to robust drug supplies and lower medicine costs.
For the 37.3 million Americans who have diabetes, insulin has become increasingly expensive. Here are four organizations dedicated to making insulin more accessible.
Civica plans to make versions of three affordable insulins available at significantly reduced costs by 2024. You can explore the other aspirations here in this article.
At this time, Civica plans a recommended price to the consumer of no more than $30 per vial and no more than $55 for a box of five pen cartridges. It believes it can have these versions of insulin available by 2024.
Fueled by billions of dollars invested by the federal government to battle the ongoing COVID-19 pandemic, companies across the BioCapital region have expanded their footprint and number of employees.
JOBS
IN THE PRESS